AU Patent

AU2010237859A1 — Fused pyrrolopyridine derivative

Assigned to Astellas Pharma Inc · Expires 2011-11-03 · 15y expired

What this patent protects

Disclosed is a fused pyrrolopyridine derivative which is useful as an active ingredient for a pharmaceutical composition, in particular a pharmaceutical composition for prevention or treatment of diseases that are caused by undesirable cytokine signaling or diseases that are caus…

USPTO Abstract

Disclosed is a fused pyrrolopyridine derivative which is useful as an active ingredient for a pharmaceutical composition, in particular a pharmaceutical composition for prevention or treatment of diseases that are caused by undesirable cytokine signaling or diseases that are caused by abnormal cytokine signaling. The inventors have intensively studied on compounds having JAK inhibitory activity, and found that the compound of the present invention, namely a fused pyrrolopyridine derivative has excellent JAK inhibitory activity and is thus useful as an agent for prevention or treatment of diseases that are caused by undesirable cytokine signaling or diseases that are caused by abnormal cytokine signaling.

Drugs covered by this patent

Patent Metadata

Patent number
AU2010237859A1
Jurisdiction
AU
Classification
—
Expires
2011-11-03
Drug substance claim
No
Drug product claim
No
Assignee
Astellas Pharma Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.